Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

101. [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program]

[Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program] Portrait de l'usage des bisphosphonates et du denosumab chez les personnes de 50 ans ou plus souffrant d'osteoporose couvertes par le regime public d'assurance medicaments [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription (...) drug insurance program] Portrait de l'usage des bisphosphonates et du denosumab chez les personnes de 50 ans ou plus souffrant d'osteoporose couvertes par le regime public d'assurance medicaments [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program] Tremblay E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA

2014 Health Technology Assessment (HTA) Database.

102. PLS3 mutations in X-linked osteoporosis with fractures. Full Text available with Trip Pro

PLS3 mutations in X-linked osteoporosis with fractures. Plastin 3 (PLS3), a protein involved in the formation of filamentous actin (F-actin) bundles, appears to be important in human bone health, on the basis of pathogenic variants in PLS3 in five families with X-linked osteoporosis and osteoporotic fractures that we report here. The bone-regulatory properties of PLS3 were supported by in vivo analyses in zebrafish. Furthermore, in an additional five families (described in less detail) referred (...) for diagnosis or ruling out of osteogenesis imperfecta type I, a rare variant (rs140121121) in PLS3 was found. This variant was also associated with a risk of fracture among elderly heterozygous women that was two times as high as that among noncarriers, which indicates that genetic variation in PLS3 is a novel etiologic factor involved in common, multi-factorial osteoporosis.

2013 NEJM

103. Building healthy bones throughout life. An evidence-informed strategy to prevent osteoporosis in Australia (Abstract)

Building healthy bones throughout life. An evidence-informed strategy to prevent osteoporosis in Australia Osteoporosis imposes a tremendous burden on Australia: 1.2 million Australians have osteoporosis and 6.3 million have osteopenia. In the 2007–08 financial year, 82 000 Australians suffered fragility fractures, of which > 17 000 were hip fractures. In the 2000–01 financial year, direct costs were estimated at $1.9 billion per year and an additional $5.6 billion on indirect costs (...) . Osteoporosis was designated a National Health Priority Area in 2002; however, implementation of national plans has not yet matched the rhetoric in terms of urgency. Building healthy bones throughout life, the Osteoporosis Australia strategy to prevent osteoporosis throughout the life cycle, presents an evidence-informed set of recommendations for consumers, health care professionals and policymakers. The strategy was adopted by consensus at the Osteoporosis Australia Summit in Sydney, 20 October 2011

2013 Clinical Practice Guidelines Portal

104. Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women

Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women UTCAT2545, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women Clinical Question In postmenopausal women can the morphology of the mandibular inferior cortex be used as a screening (...) tool aiding in the diagnosis of osteoporosis? Clinical Bottom Line Evidence shows that Eroded Appearance of the Inferior Mandibular cortex in a panoramic radiograph is an Effective Indicator for osteoporosis in postmenopausal women. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Taguchi/2004 316 women with a mean age 56.8 were recruited for this study subjects were divided into Two Groups: 159 Healthy

2013 UTHSCSA Dental School CAT Library

105. Odanacatib for male osteoporosis ? first and second line

Odanacatib for male osteoporosis ? first and second line Odanacatib for male osteoporosis – first and second line Odanacatib for male osteoporosis – first and second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Odanacatib for male osteoporosis – first and second line. Birmingham: NIHR Horizon Scanning Centre (...) (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biphenyl Compounds /therapeutic use; Humans; Male; Men; Osteoporosis /drug therapy Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham

2013 Health Technology Assessment (HTA) Database.

106. Portable Bone Mineral Density Scanners for Screening and Diagnosis of Osteoporosis: Uses, Limitations, and Guidelines

Portable Bone Mineral Density Scanners for Screening and Diagnosis of Osteoporosis: Uses, Limitations, and Guidelines TITLE: Portable Bone Mineral Density Scanners for Screening and Diagnosis of Osteoporosis: Uses, Limitations, and Guidelines DATE: 05 June 2013 RESEARCH QUESTIONS 1. What is the clinical evidence regarding the uses and limitations of portable bone mineral density (BMD) scanners for screening and diagnosis of osteoporosis compared to standard BMD scanners? 2. What (...) are the evidence-based guidelines regarding the use of portable BMD scanners for screening and diagnosis of osteoporosis? KEY MESSAGE Three non-randomized studies were identified regarding the uses and limitations of portable bone mineral density (BMD) scanners for screening and diagnosis of osteoporosis compared to standard BMD scanners. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2013, Issue 4), University of York Centre for Reviews

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

107. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. Full Text available with Trip Pro

WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. This report identifies human skeletal diseases associated with mutations in WNT1. In 10 family members with dominantly inherited, early-onset osteoporosis, we identified a heterozygous missense mutation in WNT1, c.652T→G (p.Cys218Gly). In a separate family with 2 siblings affected by recessive osteogenesis imperfecta, we identified a homozygous nonsense mutation, c.884C→A, p.Ser295*. In vitro, aberrant forms of the WNT1

2013 NEJM

108. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Full Text available with Trip Pro

Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Osteoporosis is a prevalent but underdiagnosed condition.To evaluate computed tomography (CT)-derived bone mineral density (BMD) assessment compared with dual-energy x-ray absorptiometry (DXA) measures for identifying osteoporosis by using CT scans performed for other clinical indications.Cross-sectional study.Single academic health center.1867 adults undergoing CT and DXA (n (...) = 2067 pairs) within a 6-month period over 10 years.CT-attenuation values (in Hounsfield units [HU]) of trabecular bone between the T12 and L5 vertebral levels, with an emphasis on L1 measures (study test); DXA BMD measures (reference standard). Sagittal CT images assessed for moderate-to-severe vertebral fractures.CT-attenuation values were significantly lower at all vertebral levels for patients with DXA-defined osteoporosis (P < 0.001). An L1 CT-attenuation threshold of 160 HU or less was 90

2013 Annals of Internal Medicine

109. Osteoporosis - Diagnosis and Treatment

Osteoporosis - Diagnosis and Treatment Osteoporosis: Diagnosis, Treatment and Fracture Prevention - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend theme_5_collection (...) theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Osteoporosis: Diagnosis, Treatment and Fracture Prevention Effective Date: May 1, 2011 Revised: October 1, 2012 Recommendations and Topics Scope Osteoporosis (OP) is a significant risk factor for fragility

2013 Clinical Practice Guidelines and Protocols in British Columbia

110. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) specialties and certifying boards Evidence Education * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years or older compared to non-disabled women. Regarding osteoporosis

2013 ADA Center for Evidence-Based Dentistry

111. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) specialties and certifying boards Evidence Education * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years or older compared to non-disabled women. Regarding osteoporosis

2013 ADA Center for Evidence-Based Dentistry

112. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) specialties and certifying boards Evidence Education * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years or older compared to non-disabled women. Regarding osteoporosis

2013 ADA Center for Evidence-Based Dentistry

113. Osteoporosis: Diagnosis, Treatment and Fracture Prevention

Osteoporosis: Diagnosis, Treatment and Fracture Prevention Osteoporosis: Diagnosis, Treatment and Fracture Prevention - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend (...) theme_10_collection theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Osteoporosis: Diagnosis, Treatment and Fracture Prevention Effective Date: May 1, 2011 Revised: October 1, 2012 Recommendations and Topics Scope Osteoporosis (OP) is a significant risk factor

2013 Clinical Practice Guidelines and Protocols in British Columbia

114. Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause

Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause Drug Approval Package: Duavee NDA #022247 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Duavee (conjugated estrogens and bazedoxifene) Company: Wyeth Pharmaceuticals, Inc. Application No.: 022247 Approval Date: 10/3/2013 Persons with disabilities having problems accessing

2013 FDA - Drug Approval Package

115. Osteoporosis: Prevention and Treatment

Osteoporosis: Prevention and Treatment 5 Quality Department Guidelines for Clinical Care Ambulatory Osteoporosis Guideline Team Team Lead Robert W. Lash, MD Endocrinology Team Members R. Van Harrison, PhD Medical Education Jane T. McCort, MD General Medicine Jane M. Nicholson, MD Obstetrics/Gynecology Lourdes Velez, MD Family Medicine Initial Release March, 2002 Most Recent Major Update July, 2010 Interim/Minor Revision June, 2013 Ambulatory Clinical Guidelines Oversight Connie J Standiford, MD (...) presented by the patient. Osteoporosis: Prevention and Treatment Patient population: Postmenopausal women and persons at risk for secondary osteoporosis related to long-term glucocorticoid use, organ transplant, or other medical conditions. Objective: Decrease osteoporotic fractures and their associated morbidity and mortality. Key Points Definitions Bone mineral density [BMD] correlates with skeletal strength and fracture risk. Dual-energy X-ray absorptiometry [DXA] measures BMD. A DXA T-score

2013 University of Michigan Health System

116. Transition to osteoporosis for 10% of women takes 17?years for those with normal bone density, 5?years for those with moderate osteopenia: implications for the frequency of bone density testing

Transition to osteoporosis for 10% of women takes 17?years for those with normal bone density, 5?years for those with moderate osteopenia: implications for the frequency of bone density testing Transition to osteoporosis for 10% of women takes 17 years for those with normal bone density, 5 years for those with moderate osteopenia: implications for the frequency of bone density testing | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) Transition to osteoporosis for 10% of women takes 17 years for those with normal bone density, 5 years for those with moderate osteopenia: implications for the frequency of bone density testing Article Text Electronic pages Transition to osteoporosis for 10% of women takes 17 years for those with normal bone density, 5 years for those with moderate osteopenia: implications for the frequency of bone density testing John Adam Robbins Statistics from Altmetric.com Commentary on: Gourlay ML , Fine JP

2013 Evidence-Based Medicine

117. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Full Text available with Trip Pro

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Osteoporosis medications increase bone-mineral density (BMD) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy. We compared combined teriparatide and denosumab with both agents alone.From September, 2009, to January, 2011, we enrolled postmenopausal women with osteoporosis into this randomised

2013 Lancet Controlled trial quality: predicted high

118. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Full Text available with Trip Pro

Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Nayak S, Roberts MS, Greenspan SL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study investigated the effect of various generic alendronate costs on the cost-effectiveness of osteoporosis screening and treatment in women aged 65 years and older. The authors concluded that osteoporosis screening followed by alendronate treatment provided value-for-money across a wide range of alendronate costs compared with no screening

2013 NHS Economic Evaluation Database.

119. Relationship between osteoporosis and periodontitis still unclear

Relationship between osteoporosis and periodontitis still unclear Relationship between osteoporosis and periodontitis still unclear ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted business products Purchase ADA products Access oral-health (...) information for the public and ADA Find-A-Dentist Partnerships and Commissions Learn about ADA CERP recognition, look up CERP recognized CE providers and find CE courses. Explore CODA's role and find accredited schools and programs Learn about the examinations used in licensing dentists and dental hygienists Learn about recognized dental specialties and certifying boards Evidence Education * Associated Topics Relationship between osteoporosis and periodontitis still unclear Joan Leakey Clinical Associate

2012 ADA Center for Evidence-Based Dentistry

120. Relationship between osteoporosis and periodontitis still unclear

Relationship between osteoporosis and periodontitis still unclear Relationship between osteoporosis and periodontitis still unclear ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted business products Purchase ADA products Access oral-health (...) information for the public and ADA Find-A-Dentist Partnerships and Commissions Learn about ADA CERP recognition, look up CERP recognized CE providers and find CE courses. Explore CODA's role and find accredited schools and programs Learn about the examinations used in licensing dentists and dental hygienists Learn about recognized dental specialties and certifying boards Evidence Education * Associated Topics Relationship between osteoporosis and periodontitis still unclear Joan Leakey Clinical Associate

2012 ADA Center for Evidence-Based Dentistry